Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin

Pharmacology Biochemistry and Behavior

Volumn 61, Issue 4, 1998, Pages 361-366

  Shankaran, Mahalakshmi ^a   Gudelsky, Gary A ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Dopamine; Hippocampus; MDMA; Serotonin

Indexed keywords

2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; DESIPRAMINE; DOPAMINE; SEROTONIN;

AMINE TRANSPORT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; NORADRENERGIC NERVE; PRIORITY JOURNAL; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; DESIPRAMINE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

EID: 0031770835     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00103-8     Document Type: Article

References (40)

1. 3H] paroxetine- labeled serotonin uptake sites. J. Pharmacol. Exp. Ther. 242:911-916; 1987.
2. Bischoff, S.; Scatton, B.; Korf, J.: Biochemical evidence for a transmitter role of dopamine in the rat hippocampus. Brain Res. 165:161-165; 1979.
3. 125I]iodosupride. Neuroscience 20:117-155; 1987.
4. Brodkin, J.; Mallaya, A.; Nash, J. F.: Effect of acute monoamine depletion on 3,4- methylenedioxymethamphetamine-induced toxicity. Pharmacol. Biochem. Behav. 45:647-652; 1993.
5. 3H]noradrenaline uptake and effect of DSP4 lesioning and antidepressant treatments. Neuropharmacology 35:63-70; 1996.
6. Colado, M. I.; Green, A. R.: The spin trap reagent α-phenyl-N-tert-butyl nitrone prevents 'ecstasy' -induced neurodegeneration of 5-hydroxytryptamine neurons. Eur. J. Pharmacol. 280:343-346; 1995.
7. Colado, M. I.; O'Shea, E.; Granados, R.; Murray, T. K.; Green, A. R.: In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA (ecstasy) and p-choroamphetamine but not the degeneration following fenfluramine. Br. J. Pharamacol. 121:889-900; 1997.
8. Elayan, I.; Gibb, J. W.; Hanson, G. R.; Foltz, R. L.; Lim, H. K.; Johnson, M.: Long-term alteration in the central monoaminergic systems of the rat by 2,4,5-trihydroxyamphetamine but not by 2-hydroxy-4,5-methylenedioxymethamphetamine or 2-hydroxy-4,5-methylenedioxyamphetamine. Eur. J. Pharmacol. 221:281-288; 1992.
9. Green, A R.; Cross, A. J.; Goodwin, G. M.: Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy). Psychopharmacology (Berlin) 119:247-260; 1995.
10. 2 agonists. Eur. J. Pharmacol. 264:325-330; 1994.
11. Gudelsky, G. A.; Nash, J. F.: Carrier-mediated release of serotonin by 3,4- methylenedioxymethamphetamine: Implications for serotonin-dopamine interactions. J. Neurochem. 66:243-249; 1996.
12. Gudelsky, G. A.: Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin. J. Neural Transm. 103:1397-1404; 1996.
13. Hiramatsu, M.; Kumagai, Y.; Unger, S. E.; Cho, A. K.: Metabolism of methylenedioxymethamphetamine: Formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J. Pharmacol. Exp. Ther. 254:521-527; 1990.
14. Johnson, M.; Hanson, G. R.; Gibb, J. W.: Norepinephrine does not contribute to methamphetamine- induced changes in hippocampal serotonergic system. Neuropharmacology 30:617-622; 1991.
15. 3H] dopamine release from superfused rat brain slices. Eur. J. Pharmacol. 132:269-276; 1986.
16. 4 (N-(2-chloroethyl)-N-2- bromobenzylamine - A useful denervation tool for central and peripheral noradrenaline neurons. Eur. J. Pharmacol. 72:173-188; 1981.
17. Johnson, M.; Elayan, I.; Hanson, G. R.; Foltz, R. L.; Gibb, J. W.; Lim, H. K.: Effects of 3,4- dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4- methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems. J. Pharmacol. Exp. Ther. 261:447-453; 1992.
18. Kreiss, D. S.; Lucki, I.: Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J. Pharmacol. Exp. Ther. 274:866-876; 1995.
19. Lategan, A. J.; Marien, M. R.; Colpaert, F. C.: Suppression of nigrostriatal and mesolimbic dopamine release in vivo following noradrenaline depletion by DSP4: A microdialysis study. Life Sci. 50:995-999; 1992.
20. Malberg, J.; Sabol, K. E.; Seiden, L. S.: Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J. Pharmacol. Exp. Ther. 278:258-267; 1996.
21. Mansour, A.; Meador-Woodruff, J. H.; Zhou, Q; Civelli, O.; Akil, H.; Watson, S. J.: A comparison of D1 receptor binding and mRNA in rat brain using receptor autoradiographic and in situ hybridization techniques. Neuroscience 45:359-371; 1991.
22. Nash, J. F.; Nichols, D. E.: Microdialysis studies on 3,4-methylenedioxyamphetamine (MDA) and structurally related compounds. Eur. J. Pharmacol. 200:53-56; 1991.
23. Nash, J. F.; Brodkin, J.: Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: Effect of dopamine uptake inhibitors. J. Pharmacol. Exp. Ther. 259:820-825; 1991.
24. Nash, J. F.; Meltzer, H. Y.; Gudelsky, G. A.: Elevation of serum prolactin and corticosterone concentrations after administration of 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 245:873-879; 1988.
25. O'Hearn, E.; Battaglia, G.; DeSouza, E. B.; Kuhar, M. J.; Molliver, M. E.: Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) ablation cause selective ablation of serotonergic axon terminals in forebrain: Immunocytochemical evidence for neurotoxicity. J. Neurosci. 8:2788-2803; 1988.
26. Paxinos, G.; Watson, C.: The rat brain in stereotaxic coordinates. Orlando: Academic Press; 1986.
27. Scallet, A. C.; Lipe, G. W.; Ali, S. F.; Holson, R. R.; Frith, C. H.; Slikker W., Jr.: Neuropathological evaluation by combined immunohistochemistry and degeneration-specific methods: application of methylenedioxymethamphetamine. Neurotoxicology 9:529-538; 1988.
28. Scatton, B.; Simon, H.; LeMoal, M.; Bischoff, S.: Origin of dopaminergic innervation of the rat hippocampus. Neurosci. Lett. 18:125-131; 1981.
29. Scavone, C.; Aizenstein, M. L.; Da Silva Planeta, C.; De Lucia, R.: Long-term effects of imipramine on striatal dopamine autoreceptor function: Involvement of both noradrenergic and serotonergic systems. Gen. Pharmacol. 23:397-401; 1992.
30. Schmidt, C. J.; Taylor, V. L.: Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxy methamphetamine. Biochem. Pharmacol. 36:4095-5102; 1987.
31. 2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: Reversal by L-DOPA. J. Pharmacol. Exp. Ther. 256:230-235; 1991.
32. Schmidt, C. J.; Kehne, J. H.: Neurotoxicity of MDMA: Neurochemical effects. Ann. N.Y. Acad. Sci. 600:665-680; 1990.
33. Sprague, J.; Nichols, D. E.: The monoamine oxidase-B inhibitor 1-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther. 273:667-673; 1995.
34. Stone, D. M.; Johnson, M.; Hanson, G. R.; Gibb, J. W.: Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J. Pharamacol. Exp. Ther. 128:79-87; 1988.
35. Stone, D. M.; Merchant, K. M.; Hanson, G. R.; Gibb, J. W.: Immediate and long-term effects of 3,4- methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 27:1677-1683; 1987.
36. Swanson, L. W.; Kohler, C.; Bjorklund, A.: The limbic region. 1. The septohippocampal system. In: Bjorklund, A; Hokfelt, T.; Swanson, L., eds. Handbook of chemical neuroanatomy, vol. 5, Integrated systems in the CNS. New York: Elsevier; 1987:125-177.
37. Verney, C.; Baulac, M.; Berger, B.; Alvarez, C.; Bigny, J.; Helle, K. B.: Morphological evidence for a dopaminergic terminal field in the hippocampal formation of young and adult rat. J. Neurosci. 14:1039-1052; 1985.
38. Yamamoto, B. K.; Spanos, L. J.: The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur. J. Pharmacol. 148:195-203; 1988.
39. Yamamoto, B. K.; Nash, J. F.; Gudelsky, G. A.: Modulation of methylenedioxymethamphetamine induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J. Pharmacol. Exp. Ther. 273:1063-1070; 1995.
40. Yamamoto, B.; Pehek, E.: A neurochemical heterogeneity of the rat striatum as measured by in vivo electrochemistry and microdialysis. Brain Res. 506:236-242; 1990.